California Public Employees Retirement System Reduces Stake in IDEXX Laboratories, Inc. $IDXX

California Public Employees Retirement System lowered its position in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 3.7% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 156,525 shares of the company’s stock after selling 6,064 shares during the period. California Public Employees Retirement System owned about 0.20% of IDEXX Laboratories worth $87,950,000 at the end of the most recent reporting period.

A number of other hedge funds also recently bought and sold shares of IDXX. SHP Wealth Management purchased a new position in IDEXX Laboratories in the fourth quarter worth about $26,000. Virtus Advisers LLC purchased a new stake in shares of IDEXX Laboratories during the 3rd quarter valued at about $26,000. Park Place Capital Corp purchased a new stake in shares of IDEXX Laboratories during the 4th quarter valued at about $29,000. WealthCollab LLC bought a new position in shares of IDEXX Laboratories in the 2nd quarter worth approximately $30,000. Finally, Caitong International Asset Management Co. Ltd bought a new position in shares of IDEXX Laboratories in the 3rd quarter worth approximately $36,000. Hedge funds and other institutional investors own 87.84% of the company’s stock.

IDEXX Laboratories Stock Performance

IDXX opened at $567.44 on Monday. The company has a debt-to-equity ratio of 0.19, a quick ratio of 0.82 and a current ratio of 1.12. The stock has a market capitalization of $44.76 billion, a price-to-earnings ratio of 41.78, a PEG ratio of 3.10 and a beta of 1.55. The company has a fifty day moving average of $554.49 and a 200 day moving average of $599.33. IDEXX Laboratories, Inc. has a fifty-two week low of $513.02 and a fifty-two week high of $769.98.

IDEXX Laboratories (NASDAQ:IDXX) last announced its quarterly earnings results on Tuesday, May 5th. The company reported $3.47 EPS for the quarter, topping the consensus estimate of $3.41 by $0.06. IDEXX Laboratories had a net margin of 24.63% and a return on equity of 70.87%. The business had revenue of $1.14 billion for the quarter, compared to analysts’ expectations of $1.12 billion. During the same quarter in the previous year, the company earned $2.91 EPS. The business’s quarterly revenue was up 14.3% compared to the same quarter last year. IDEXX Laboratories has set its FY 2026 guidance at 14.450-14.900 EPS. As a group, sell-side analysts forecast that IDEXX Laboratories, Inc. will post 14.68 earnings per share for the current fiscal year.

Analysts Set New Price Targets

IDXX has been the subject of several recent research reports. Stifel Nicolaus cut their target price on shares of IDEXX Laboratories from $775.00 to $675.00 and set a “buy” rating for the company in a research report on Tuesday, March 31st. UBS Group decreased their price target on shares of IDEXX Laboratories from $730.00 to $640.00 and set a “neutral” rating on the stock in a research report on Tuesday, April 28th. Citigroup began coverage on shares of IDEXX Laboratories in a research note on Wednesday, April 15th. They set a “neutral” rating and a $650.00 price target on the stock. Wall Street Zen downgraded shares of IDEXX Laboratories from a “buy” rating to a “hold” rating in a research report on Sunday, July 12th. Finally, Weiss Ratings lowered IDEXX Laboratories from a “hold (c+)” rating to a “hold (c)” rating in a research note on Tuesday, July 14th. Six analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $751.00.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.